Cargando…

The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: results of the HOVON‐107 study

BACKGROUND: Plerixafor (PFX) mobilizes CD34+ cells into circulation by disrupting the CXCR4 binding of the hematopoietic stem cell in its bone marrow niche. STUDY DESIGN AND METHODS: in the prospective HOVON‐107 study (www.hovon.nl) 23 allogeneic HLA–identical sibling donors received one or two subc...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Greef, Georgine E., Braakman, Eric, van der Holt, Bronno, Janssen, Jeroen J.W.M., Petersen, Eefke, Vucinic, Vladimir, Thuss, Nicole, Grootes, Meriam, Cornelissen, Jan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2018
Materias:	Cellular Therapies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380058/ https://www.ncbi.nlm.nih.gov/pubmed/30548284 http://dx.doi.org/10.1111/trf.15037

Ejemplares similares

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
por: Broers, Annoek E. C., et al.
Publicado: (2022)

The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed
por: Bakunina, Katerina, et al.
Publicado: (2021)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

Plerixafor
por: Slater, Susan
Publicado: (2012)

CT-107: Coronavirus Disease in Bone Marrow Transplant (BMT) Recipients at Edgardo Rebagliati Martins Hospital (HNERM) Lima, Peru
por: Bazan, Susy, et al.
Publicado: (2021)

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
por: Rijneveld, Anita W., et al.
Publicado: (2022)

Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation
por: Nadeau, Michelle, et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Potential of Membranes Surrounding the Fetus as Immunoprotective Cell-Carriers for Allogeneic Transplantations
por: Togarrati, Padma Priya, et al.
Publicado: (2019)

Immune tolerance strategies in siblings with infantile Pompe disease — Advantages for a preemptive approach to high-sustained antibody titers
por: Stenger, Elizabeth O., et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
por: Oliva, Stefania, et al.
Publicado: (2021)

Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease
por: García-Sancho, Javier, et al.
Publicado: (2017)

Insulin Pump for Type 2 Diabetes: Use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes
por: Reznik, Yves, et al.
Publicado: (2013)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2020)

Prognostic plasma biomarkers of early complications and graft‐versus‐host disease in patients undergoing allogeneic hematopoietic stem cell transplantation
por: Balakrishnan, Balaji, et al.
Publicado: (2020)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

De Novo Circulating Antidonor's Cell Antibodies During Induced Acute Rejection of Allogeneic Myofibers in Myogenic Cell Transplantation: A Study in Nonhuman Primates
por: Skuk, Daniel, et al.
Publicado: (2017)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Correction to: Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial
por: Hölig, Kristina, et al.
Publicado: (2021)

S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL
por: Van Dijck, Ruben, et al.
Publicado: (2023)

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
por: Kersten, Marie José, et al.
Publicado: (2022)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
por: Hassanein, Mona, et al.
Publicado: (2021)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023)

Triptans in clinical practice: the basic scientist’s point of view
por: Buzzi, M. Gabriella
Publicado: (2001)

Clinical experience with triptans
por: Zanchin, Giorgio, et al.
Publicado: (2001)

Triptans: the experience of a clinical pharmacologist in clinical practice
por: Pini, Luigi Alberto, et al.
Publicado: (2001)

Anticonvulsant drugs in migraine prophylaxis
por: Frediani, Fabio, et al.
Publicado: (2001)

Up to date on the use of triptans for child and adolescent migraine: state of the art
por: Calderoni, Dario, et al.
Publicado: (2001)

Menstrual migraine
por: Moschiano, Franca, et al.
Publicado: (2001)

New strategies for the treatment of migraine attacks
por: Genco, Sergio, et al.
Publicado: (2001)

Diagnostic and therapeutic guidelines for migraine. Italian Society for the Study of Headaches (SISC)
por: Gallai, Virgilio, et al.
Publicado: (2001)

Clinical Characteristics of De Novo Heart Failure and Acute Decompensated Chronic Heart Failure: Are They Distinctive Phenotypes That Contribute to Different Outcomes?
por: Raffaello, Wilson Matthew, et al.
Publicado: (2021)

Rationale for and Practical Use of Sacubitril/Valsartan in the Patient’s Journey with Heart Failure and Reduced Ejection Fraction
por: Gori, Mauro, et al.
Publicado: (2021)

Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids
por: Fenton, Chloe, et al.
Publicado: (2021)

How to Implant His Bundle and Left Bundle Pacing Leads: Tips and Pearls
por: Ponnusamy, Shunmuga Sundaram, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_glmhi2svv4vm1qck6j9p6770ne